Doptelet Pill — Competitive Intelligence Brief

Doptelet Pill (Doptelet Pill) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Thrombopoietin receptor agonist. Area: Hematology.

marketed Thrombopoietin receptor agonist TPO receptor (TPOR/MPL) Hematology Small molecule

Target snapshot

Doptelet Pill (Doptelet Pill) — Hvidovre University Hospital. Doptelet (avatrombopag) is a thrombopoietin receptor agonist that stimulates platelet production by binding to the TPO receptor on bone marrow megakaryocytes.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Doptelet Pill TARGET	Doptelet Pill	Hvidovre University Hospital	marketed	Thrombopoietin receptor agonist	TPO receptor (TPOR/MPL)
Promacta	ELTROMBOPAG	Novartis	marketed	Thrombopoietin Receptor Agonist	Thrombopoietin receptor	2008-01-01
Nplate	ROMIPLOSTIM	Amgen	marketed	Thrombopoietin Receptor Agonist [EPC]	Thrombopoietin receptor	2008-01-01
Eltrombopag (EPAG)	Eltrombopag (EPAG)	Centro de Atencion e Investigacion Medica	marketed	Thrombopoietin receptor agonist	TPO receptor (c-Mpl)
eltrombopag combining rituximab	eltrombopag combining rituximab	Institute of Hematology & Blood Diseases Hospital, China	marketed	Combination therapy: thrombopoietin receptor agonist + monoclonal antibody	TPO receptor (c-Mpl) and CD20
rhTPO combined with Herombopag + CsA	rhTPO combined with Herombopag + CsA	Peking Union Medical College Hospital	marketed	Thrombopoietin receptor agonist combination with immunosuppressant	Thrombopoietin receptor (MPL); calcineurin (CsA target)
CsA+ATG+Herombopag	CsA+ATG+Herombopag	Peking Union Medical College Hospital	marketed	Immunosuppressive agent + thrombopoietin receptor agonist combination	Calcineurin (CsA); T lymphocytes (ATG); thrombopoietin receptor (eltrombopag)

Recent regulatory actions (last 90 days)

• 2026-03-16 — Promacta · FDA · approved · US · Novartis

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Thrombopoietin receptor agonist class)

1. Centro de Atencion e Investigacion Medica · 2 drugs in this class
2. Institute of Hematology & Blood Diseases Hospital, China · 2 drugs in this class
3. Jiangsu HengRui Medicine Co., Ltd. · 2 drugs in this class
4. Hvidovre University Hospital · 1 drug in this class
5. Kyowa Kirin Korea Co., Ltd. · 1 drug in this class
6. Peking Union Medical College Hospital · 1 drug in this class
7. PharmaEssentia Japan K.K. · 1 drug in this class
8. Qilu Pharmaceutical Co., Ltd. · 1 drug in this class
9. Shenyang Sunshine Pharmaceutical Co., LTD. · 1 drug in this class
10. Amgen · 1 drug in this class